Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroOne Medical Technologies Corporation filings document the public-company records of a Nasdaq-listed medical technology issuer developing thin-film electrode and ablation systems for neurological procedures. Current reports and proxy materials disclose operating results, regulatory and clinical update categories, capital-structure actions, governance matters and stockholder voting items.
The company’s SEC record includes Form 8-K disclosures for financial results, Nasdaq listing compliance, certificate amendments, reverse stock split actions, officer and compensation matters, and annual-meeting scheduling. Its definitive proxy statement covers director elections, auditor ratification, equity incentive plan amendments, stockholder proposals and other governance votes tied to NeuroOne’s common stock.
NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.
NEUROONE MEDICAL TECHNOLOGIES Corp executive David J. Wambeke, the company’s Chief Business Officer, filed an initial Form 3 reporting his beneficial ownership in the company. The filing does not list any insider buy or sell transactions; it simply establishes his status as a reporting officer.
NeuroOne Medical Technologies Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held April 3, 2026 at its Eden Prairie, MN offices. Stockholders will vote to elect two Class III directors, ratify Baker Tilly as auditor, approve a Board-authorized reverse stock split (a 1-for-2 to 1-for-15 range), approve an amendment to the 2025 Equity Incentive Plan, and authorize adjournments to solicit additional proxies.
The record date for voting is February 20, 2026; 50,693,017 shares of Common Stock were outstanding as of that date. The Board may select the final reverse-split ratio and timing if stockholders approve the range.
NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.
Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a Form 4 transaction involving company common stock. On this date, 7,376 shares were disposed of at a price of $0.68 per share as a tax-withholding disposition rather than an open-market sale. Following this transaction, Mertens directly owned 153,047 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.
NeuroOne Medical Technologies Corp officer Mark Christianson reported a tax-related share disposition. On February 18, 2026, he disposed of 1,812 shares of common stock at $0.68 per share to cover tax withholding. Following this transaction, he directly owns 228,920 common shares of the company.
NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.
NeuroOne Medical Technologies Corporation reported fiscal first-quarter 2026 results and raised its outlook for the full year. For the quarter ended December 31, 2025, product revenue was $2.9 million, slightly below $3.3 million a year earlier due to a large initial stocking order in the prior-year period, but up 5.5% from $2.7 million in the previous quarter. Product gross profit was $1.6 million, or 54.2% of revenue.
The company reported a net loss of $1.4 million, or $0.03 per share, compared with net income of $1.8 million, or $0.06 per share, a year ago, when results included $3.0 million of one-time license revenue. As of December 31, 2025, NeuroOne held $3.6 million in cash and cash equivalents, $6.8 million of working capital, and no debt, and believes it is funded through fiscal 2026. Management now expects fiscal 2026 product revenue of at least $10.5 million, at least 17% higher than fiscal 2025.
NeuroOne Medical Technologies reported a net loss of $1.4 million for the quarter ended December 31, 2025, after earning $1.8 million in the prior-year period, mainly because last year included $3.0 million of one-time license revenue from its Zimmer agreement. Product revenue from its cleared neuromodulation devices was $2.9 million, down modestly from $3.3 million, and product gross margin slipped to 54.2% from 58.9% due to pricing mix and higher costs.
Cash and cash equivalents were $3.6 million at December 31, 2025, versus $6.6 million at September 30, 2025, as operating activities used $3.1 million of cash in the quarter. Management believes existing cash, expected Zimmer-related product revenues and planned expense reductions can fund operations through September 2026, but still states that substantial doubt exists about the company’s ability to continue as a going concern. NeuroOne remains highly dependent on a single major customer for product revenue and on third-party manufacturers, and it has received a Nasdaq notice for not meeting the minimum bid price requirement, with an extension to regain compliance by May 4, 2026.
NeuroOne Medical Technologies Corporation filed an Amendment No. 1 to its annual report to add the Part III sections that would normally come from its proxy, covering board structure, executive pay, ownership and auditor information.
The filing describes a three-class board led by non-executive chairman Paul Buckman, with separate audit, compensation, and nominating and corporate governance committees, all composed of Nasdaq-independent directors other than the CEO. It details 2025 compensation for CEO David Rosa (total $1,154,436), COO Christopher Volker and CFO Ronald McClurg, including base salaries, cash bonuses paid at 94% of target and significant stock option grants.
The amendment also discloses non-employee director retainers (generally $50,000, with $100,000 for the chair) plus equity awards, shows that Merchant Adventure Fund, L.P. beneficially owns 8.3% of common stock, and that all directors and officers as a group hold 11.8%. It notes related-party participation in a 2024 private placement and a 2025 public offering, and lists 2025 audit fees to Baker Tilly US, LLP of $407,111.